| 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-13 | 南山战新投 | 千万级人民币 | Pre-A+轮 | | 2025-11-04 | 创东方投资 | 未披露 | Pre-A轮 | | 2025-10-14 | HongShan红杉中国 | 数千万人民币 | 天使+ | | | 江西全控资本 | | | | 2023-11-30 | 仙瞳资本 | 数千万人民币 | 天使轮 | | | 力合科创 | | | | 2023-02-28 | 深圳津北投资合伙企业(有限合伙) | 数百万人民币 | 种子轮 | 证券之星消息，根据天眼查APP于11月13日公布的信息整理，深圳津渡生物医学科技有限公司Pre-A+轮 融资，融资额千万级人民币，参与投资的机构包括南山战新投。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 津渡生科（OxTium Technology）致力于开发多模态医学诊断大模型，主要聚焦多组学分析（RNA组、 DNA组 ...

Core Insights - Chuangdong Investment announced a Pre-A round investment of tens of millions of RMB in Shenzhen Jindu Biomedical Technology Co., Ltd. (referred to as "Jindu Bio") on October 24, with Jiangxi Jin Kong participating in the investment, bringing Jindu Bio's total financing to nearly 100 million RMB to date [1] Company Overview - Jindu Bio possesses the cutting-edge global biological science model GeneLLM and has developed a one-stop biological science research platform called BioFord, along with AI products such as the AI4S Lab digital life science laboratory [1] - The core team, led by founder Dr. Jin Yongcheng, consists entirely of members from the University of Oxford, showcasing a multidisciplinary background in life sciences and artificial intelligence, which highlights the company's composite team characteristics [1] Investment Context - The investment by Chuangdong Investment aligns with its focus on the major sectors of AI and health, indicating a strategic interest in companies that integrate advanced technology with life sciences [1]